AI System Validation for GxP Compliance
Benefits and Challenges of AI
AI offers significant benefits to life sciences companies by accelerating drug development, improving trial design, enhancing signal detection, and automating pharmacovigilance processes. Advanced analytics and machine learning enable faster insights from growing volumes of clinical and real-world data. However, maintaining GxP compliance presents challenges, as AI systems differ from traditional validated systems. AI models are probabilistic rather than deterministic, rely on training and test datasets, and may change behavior over time. Validation therefore requires ongoing performance monitoring, management of data drift, transparency and explainability of outputs, and robust controls to address bias, reproducibility, and auditability in regulated environments.
Starsphere AI Validation Services
Starsphere, in partnership with HiroPharmaConsulting® Co., Ltd, offers specialized validation services for AI systems used in life sciences. This service is built on the patent-approved HPVM (AI-PV HiroPharma Validation Method), a structured approach designed to address the unique challenges of AI validation. Unlike traditional systems, AI models require ongoing performance monitoring and evaluation of probabilistic outputs. HPVM provides a risk-based, GxP-aligned framework that ensures transparency, traceability, and regulatory compliance throughout the AI lifecycle. Together, Starsphere and HiroPharmaConsulting deliver practical, audit-ready validation solutions tailored to pharmacovigilance and regulated AI applications.
HiroPharma Consulting (HPC) is a life sciences consulting firm specializing in pharmacovigilance, regulatory compliance, and AI system assurance. It helps organizations strengthen drug safety and meet global and Japanese requirements through risk-based approaches. HPC developed HPVM, (HiroPharma Validation Method) a framework for validating AI-driven pharmacovigilance systems focused on transparency, reliability, explainability, and audit readiness.
Hirotsugo Atsumaru
Representative Director HiroPharmaConsulting® Co., Ltd
Mr. Hirotsugu Atsumaru, Founder and President of HiroPharma Consulting, brings extensive experience in pharmacovigilance, regulatory compliance, and system validation across global and Japanese requirements. He founded the company to address GVP CSV and the need for practical validation approaches for AI systems in regulated environments, and contributes to ISPE GAMP5 AI guidance dissemination in Japan.
